This study aimed at exploring several brain metastatic prognostic scores in patients with renal cell carcinoma.
We retrospectively analyzed data of 93 metastatic renal cell carcinoma patients who were diagnosed with brain metastases between October 2005 and July 2016 who received targeted therapy. Potential prognostic factors (RTOG RPA, BS-BM, and a newly developed score CERENAL) were analyzed.
A total of 75 patients received targeted therapy. All scores showed prognostic value in progression-free survival after first-line treatment with CERENAL being the sole independent prognostic factor associated with improved duration of first-line treatment. Both RTOG RPA and CERENAL were potential prognosticators for overall survival, whereas only the CERENAL score was associated with prolonged disease-specific survival.
Several prognostic scores can be useful to predict survival of patients with brain metastases from renal cancer, especially the newly developed CERENAL score.
Anticancer research. 2019 Jun [Epub]
Ziad El Ali, Sylvie Rottey, Philippe Barthelemy, Nuria Kotecki, Ruben VAN Paemel, Daniel Devrient, Ahmad Awada, Thierry Gil, Diane Pannier, Thomas Ryckewaert, Waissi Waisse, Jean-Baptiste Clavier, Nicolas Penel, Tijl Vermassen
Medical Oncology Clinic, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium ., Department of Medical Oncology, Ghent University Hospital, Ghent, Belgium., Medical Oncology Department, Hôpitaux Universitaires de Strasbourg, Strasbourg, France., Medical Oncology Clinic, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium., Radiotherapy Department, Jules Bordet Institute, Brussels, Belgium., Department of General Oncology, Centre Oscar Lambret, Lille, France., Radiation Oncology Department, Comprehensive Cancer Center Paul Strauss, Strasbourg, France.